Bookmark
Forward
QuickView for Anidulafungin (compound)
PubChem
| Name: | anidulafungin |
|---|---|
| PubChem Compound ID: | 166548 |
| Molecular formula: | C58H73N7O17 |
| Molecular weight: | 1140.24 g/mol |
| Synonyms: |
Echinocandin B, 1-((4R,5R)-4,5-dihydroxy-N2-((4-(pentyloxy)(1,1':4',1-terphenyl)-4-yl)carbonyl)-L-ornithine); Anidulafungin [USAN:INN]; V-Echinocandin; Anidulafungin; 166663-25-8; VER-002; LY-303366; Eraxis
|
DrugBank
Identification
| Name: | anidulafungin |
|---|---|
| Name (isomeric): | DB00362 |
| Drug Type: | small molecule |
| Brand: | Eraxis |
| Category: | Antibiotics, Antifungal |
| CAS number: | 166663-25-8 |
Pharmacology
| Indication: | For use in the treatment of the following fungal infections: Candidemia and other forms of <i>Candida</i> infections (intra-abdominal abscess, and peritonitis), Aspergillus infections, and esophageal candidiasis. Also considered an alternative treatment for oropharyngeal canaidiasis. |
|---|---|
| Pharmacology: |
Anidulafungin is a semi-synthetic lipopeptide synthesized from a fermentation product of Aspergillus nidulans. Anidulafungin is an echinocandin, a class of antifungal drugs that inhibits the synthesis of 1,3-β-D-glucan, an essential component of fungal cell walls. Anidulafungin is active in vitro against many Candida, as well as ...
show more » |
| Mechanism of Action: | Anidulafungin is a semi-synthetic echinocandin with antifungal activity. Anidulafungin inhibits glucan synthase, an enzyme present in fungal, but not mammalian cells. This results in inhibition of the formation of 1,3-β-D-glucan, an essential component of the fungal cell wall, ultimately leading to osmotic instability and cell death. |
| Protein binding: | 84% |
| Biotransformation: | Hepatic metabolism of anidulafungin has not been observed. Anidulafungin is not a clinically relevant substrate, inducer, or inhibitor of cytochrome P450 (CYP450) isoenzymes. Anidulafungin undergoes slow chemical degradation at physiologic temperature and pH to a ring-opened peptide that lacks antifungal activity. |
| Route of elimination: | Less than 1% of the administered radioactive dose was excreted in the urine. Anidulafungin is not hepatically metabolized. |
| Half Life: | 40-50 hours |
| Clearance: | 1 L/h |
| Toxicity: | During clinical trials a single 400 mg dose of anidulafungin was inadvertently administered as a loading dose. No clinical adverse events were reported. The maximum non-lethal dose of anidulafungin in rats was 50 mg/kg, a dose which is equivalent to 10 times the recommended daily dose for esophageal candidiasis (50mg/day). |
| Affected organisms: | Aspergillis, Candida and other fungi |
Targets
